Device Trial Radar · NCT07603284
Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
Nov 2, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- DexCom, Inc.Public (DXCM)
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to understand how using real-time continuous glucose monitoring (RT-CGM) can help people with Type-2 diabetes on insulin in Saudi Arabia.
Conditions
- Type 2 Diabetes on Insulin
Interventions
Real-Time Continuous Glucose MonitoringDevice
real time continuous glucose monitoring utilizing a CGM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
King Fahad Medical City
Riyadh, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.